Vanguard Group Inc Zynerba Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.5 - $0.72 $505 - $727	1,010 Added 0.05%	2,179,600 $1.16 Million
Q3 2022 Nov 14, 2022	BUY	$0.87 - $1.36 $201,840 - $315,520	232,000 Added 11.92%	2,178,590 $1.6 Million
Q1 2022 May 13, 2022	BUY	$1.83 - $3.02 $226,427 - $373,667	123,731 Added 6.79%	1,946,590 $3.99 Million
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $99,046 - $147,881	-34,391 Reduced 1.85%	1,822,859 $5.25 Million
Q3 2021 Nov 12, 2021	SELL	$3.72 - $5.35 $69,270 - $99,622	-18,621 Reduced 0.99%	1,857,250 $7.88 Million
Q2 2021 Aug 13, 2021	BUY	$3.83 - $5.98 $7.18 Million - $11.2 Million	1,875,871 New	1,875,871 $9.92 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.